Overview

* Foghorn Therapeutics ( FHTX ) Q2 collaboration revenue rises to $7.6 mln, driven by Lilly partnership

* Net loss for Q2 decreases to $17.9 mln compared to $23.0 mln last year

* Co maintains strong cash position with $198.7 mln, runway into 2028

Outlook

* Company has cash runway into 2028

* FHD-909 Phase 1 trial remains on track

Result Drivers

* FHD-909 TRIAL - Phase 1 trial for SMARCA4-mutated cancers enrolling well, per CEO Adrian Gottschalk

* SYNERGISTIC DATA - Preclinical data shows FHD-909 enhances anti-tumor activity with pembrolizumab and KRAS inhibitors

* DEGRADER PROGRAMS - Progress in selective CBP, EP300, and ARID1B degrader programs with updates expected in Q4 2025

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 $7.56

Collabor mln

ation

Revenue

Q2 EPS -$0.28

Q2 Net -$17.94

Income mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Foghorn Therapeutics Inc ( FHTX ) is $11.50, about 55.3% above its August 4 closing price of $5.14

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)